Loading...
Please wait, while we are loading the content...
Similar Documents
Roche ’ s personalised medicine entrectinib shrank tumours harbouring NTRK , ROS 1 or ALK gene fusions in children and adolescents
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2019 |
| Abstract | 1/4 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents ● Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) fusions, including those in the central nervous system ● Data featured in the ASCO presscast on Wednesday, 15 May, and will be presented at the 2019 ASCO Annual Meeting on Sunday, 2 June |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.roche.com/dam/jcr:0da1227f-06a2-4c55-a64f-06bce52a0a58/190516_IR_Entrectinib_STARTRK-NG_ASCO_%20EN.pdf |
| Alternate Webpage(s) | http://hugin.info/174806/R/2244483/886345.pdf |
| Alternate Webpage(s) | https://www.roche.com/dam/jcr:689b5447-8712-43a6-b383-9f7d2fe4013e/20190516_Entrectinib%20STARTRK-NG%20ASCO_%20EN.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |